| | MARCH 20178Consultants ReviewMarketsandMarkets is the largest market research firm worldwide in terms of premium market research reports published annually. Siddharth brings more than 16 years of Healthcare Industry experience to MnM. He has worked with Tertiary care hospitals (US & India), Government of India & Malaysia projects as well as MNCs.he public healthcare scenario in India is not in a good shape and needs serious preventive diagnosis. Recently, Noble Laureate Amartya Sen stated that the India public healthcare had witnessed a slide over the past few decades with media and politicians ignoring the sector largely. Well to an extent it is true but that has not stopped people from taking some strong initiatives in 2017. Here are few glimpse-India's Small Step to Eradicate MalariaIn 2015, approximately 798 people died due to Malaria, Dengue and Japanese Encephalitis and till July 2016, 21 deaths due to dengue, 57 deaths due to malaria were reported by Health Minister Nadda in Lok Sabha (Financial express, July 29, 2016). Malaria, Dengue and Japanese Encephalitis remains one of the major concerns for the country every year. Despite efforts to eradicate, it remains a problem for the government and the people of India.In one of its first PPP models and also a first major step to eradicate malaria, the Indian Council of Medical Research has signed an agreement (Feb 2016) with Sun Pharma as part of the government strategy to eliminate malaria by 2030. The first phase of the project is expected to be launched across 1,233 villages in Mandla in January 2017. NIRTH, Government of Madhya Pradesh and FDEC (Independent Project Management) are expected to work jointly on the malaria elimination program by use of vector control (Use of Long Lasting Bednets (LLINs) and case management (rapid on the spot diagnosis and prompt treatment) as per national or WHO guidelines. Sun Pharma is expected to fund as well as execute this program over a time period of three to five years, covering over 2,00,000 households in Mandla.Although this initiative is unique, the only concern that comes to my mind is that this should not lead to drug monopoly of any one particular company. Malaria drugs are manufactured by companies such as Cipla, Sanofi, Abbott, etc. and with this unique PPP model, Mandla (Target city) is expected to be flooded with drugs from one particular company. At present, there is limited clarity on whether there are any measures to control monopoly or not. The good news is that if this PPP model is successful, then, we can expect more such IN MY OPINIONBy Siddharth Dutta, Associate Vice President Healthcare, MarketsandMarketsINDIAN HEALTHCARE OUTLOOK IN 2017T
< Page 7 | Page 9 >